Our long-term ambition is firmly centered on driving patient impact through growth and innovation – expanding our product portfolio and advancing a pipeline of therapies that redefine standards of care. We believe this next chapter will deliver meaningful outcomes for patients while continuing to strengthen our high-performing organization.
Within this ambition, we are deepening our focus in rare disease, where our expertise, track record, and relationships uniquely position us well to be successful for our patients and our shareholders. At the same time, we will continue to unlock the full potential of our portfolio including our first-in-class bispecific antibody used to treat HER2+ cancers, including opportunities beyond rare disease. Our success in rare sleep and rare epilepsy – including two blockbuster franchises – and our expanding presence in rare oncology set the foundation for continued success. This is about sharpening our strategy to where Jazz is best positioned to deliver the greatest impact for patients and sustained value for shareholders. We feel an urgency to address unmet medical needs, which is fundamental to our purpose: to innovate to transform the lives of patients and their families.
Hear from Renee Gala, President and CEO, on sharpening our strategic focus
A strategic focus on rare disease will further enable us to take earlier, smarter risks in areas we know well – all on behalf of patients. Building on our 20+ year legacy, we've delivered results and built the capabilities required to excel in rare disease – identifying underserved patient populations, developing first-in-class patient support services and executing rapid development plans where the need is great, to name just a few.
We are equally proud of our ability to identify external innovation and seamlessly bring those medicines into our portfolio through acquisitions or strategic partnerships. Moving with urgency and discipline, we have secured regulatory approvals and then commercially launched those medicines with meaningful access support for patients. For example, in 2025 following the Chimerix acquisition, we launched a first-of-its-kind targeted therapy that treats rare brain cancer affecting adults and children - the first FDA-approved medicine for this type of cancer. We believe there is more we can do and we are well positioned to expand beyond our current therapeutic areas of focus into other areas. This is where you can expect us to focus and how we will drive sustainable growth for our shareholders and meaningful impact for patients.
We are sharpening our strategic focus and leaning into what we do exceptionally well, continuing to be laser focused on flawless execution and organizational performance. Our incredibly talented and passionate team demands nothing less for the patients and families we serve.
